Uqba Khan Humaira Rizvi Dahlia Sano Jane Chiu Tarik Hadid
10.1186/s40425-017-0213-x
J Immunother Cancer
2017 Feb 21;5:13.
hyperthyroidism immunotherapy myxedema crisis nivolumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/28239466/
Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Myxedema / chemically induced
Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Myxedema / chemically induced Case Reports Carcinoma, Squamous Cell / drug therapy Female Humans Lung Neoplasms / drug therapy Middle Aged Myxedema / drug therapy Nivolumab Thyroxine / therapeutic use Antibodies, Monoclonal Antineoplastic Agents Nivolumab Thyroxine
PMC5319087
28239466
Nivolumab induced myxedema crisis
2017